Rouleau J

Rouleau J

Université de Montréal

H-index: 146

North America-Canada

About Rouleau J

Rouleau J, With an exceptional h-index of 146 and a recent h-index of 86 (since 2020), a distinguished researcher at Université de Montréal, specializes in the field of medicine.

His recent articles reflect a diverse array of research interests and contributions to the field:

Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from …

Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial

Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure

Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment

EFFECTS OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF KIDNEY RISK

SACUBITRIL/VALSARTAN, TREATMENT-RELATED HYPOTENSION, AND LEFT VENTRICULAR EJECTION FRACTION IN THE PARAGON-HF TRIAL

EFFECT OF SACUBITRIL/VALSARTAN ACCORDING TO POLYPHARMACY STATUS IN PARAGON-HF

ABDOMINAL OBESITY AND OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE PARAGON-HF TRIAL

Rouleau J Information

University

Position

Professor of Medicine

Citations(all)

129090

Citations(since 2020)

35375

Cited By

110371

hIndex(all)

146

hIndex(since 2020)

86

i10Index(all)

496

i10Index(since 2020)

299

Email

University Profile Page

Google Scholar

Rouleau J Skills & Research Interests

medicine

Top articles of Rouleau J

Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from …

European Journal of Heart Failure

2024/1

Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial

European Heart Journal

2024/4/21

Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure

Journal of the American College of Cardiology

2024/4/6

Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment

2024/4/6

EFFECTS OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF KIDNEY RISK

Journal of the American College of Cardiology

2024/4/2

SACUBITRIL/VALSARTAN, TREATMENT-RELATED HYPOTENSION, AND LEFT VENTRICULAR EJECTION FRACTION IN THE PARAGON-HF TRIAL

Journal of the American College of Cardiology

2024/4/2

EFFECT OF SACUBITRIL/VALSARTAN ACCORDING TO POLYPHARMACY STATUS IN PARAGON-HF

Journal of the American College of Cardiology

2024/4/2

ABDOMINAL OBESITY AND OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE PARAGON-HF TRIAL

Journal of the American College of Cardiology

2024/4/2

Sacubitril/Valsartan-Related Hypotension in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction

Journal of the American College of Cardiology

2024/3/25

Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI

The Journal of Heart and Lung Transplantation

2020/4/1

Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review

2024/3/1

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT

International Journal of Cardiology

2024/2/1

Clinical Heart fAilure Management Program: Changing the practice by partnering primary care and specialists (CHAMP-HF)

IJC Heart & Vasculature

2024/2/1

Independent prognostic importance of blood urea nitrogen to creatinine ratio in heart failure

European journal of heart failure

2024/2

Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan

ESC Heart Failure

2024/2

Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9—Pragmatic Research and Innovation through …

Trials

2024/1/23

Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial

Circulation

2024/1/23

Long-Term Outcomes of Resynchronization–Defibrillation for Heart Failure

New England Journal of Medicine

2024/1/18

Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan

Heart Failure

2023/7/1

Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial

European Heart Journal

2023/6/21

See List of Professors in Rouleau J University(Université de Montréal)